Previous close | 4.6100 |
Open | 4.6100 |
Bid | 4.3100 x 100 |
Ask | 4.3900 x 100 |
Day's range | 4.2300 - 4.7000 |
52-week range | 1.1110 - 6.7200 |
Volume | |
Avg. volume | 1,322,285 |
Market cap | 491.915M |
Beta (5Y monthly) | 2.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Explore key financial outcomes, strategic partnerships, and innovative developments from Absci Corp's first quarter of 2024.
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.